European Monitoring Centre for Drugs and Drug Addiction. (2014) Report on the risk assessment of 5-(2-aminopropyl)indole in the framework of the Council Decision on new psychoactive substances. Luxembourg: Publications Office of the European Union.
Preview | Title | Contact |
---|---|---|
PDF (Report on the risk assessment of 5-(2-aminopropyl)indole )
- Published Version
945kB |
This report presents the data and findings of the risk assessment on the new psychoactive substance, 5-(2-aminopropyl)indole, that was conducted by the Scientific Committee of the EMCDDA. Concerns over the availability and use of this stimulant drug in the European Union led to an assessment of the health and social risks posed by the substance, and, consequently, its control across the EU Member States.
Table of contents:
• Foreword
• Introduction
• EMCDDA actions on monitoring and responding to new drugs
• EMCDDA–Europol Joint Report on 5-(2-aminopropyl)indole: a summary
• Risk Assessment Report of a new psychoactive substance: 5-(2-aminopropyl)indole
• Annex 1: Technical report on 5-(2-aminopropyl)indole
• Annex 2: Study examining the inhibition of human monoamine oxidase (MAO) by the new psychoactive substance 5-(2-aminopropyl)indole (5-IT)
• Council Implementing Decision 2013/496/EU on subjecting 5-(2-aminopropyl)indole to control measures
• Abbreviations
• Participants of the risk assessment meeting
B Substances > New (novel) psychoactive substances > Aminoindanes / Arylalkylamines / Arylcyclohexylamines
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
L Social psychology and related concepts > Legal availability or accessibility
VA Geographic area > Europe
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page